Overview

Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Status:
Unknown status

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) in unresectable advanced esophageal cancer. The usefulness of the this regimen is evaluated by RECIST, time to progression and median survival time.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Wakayama Medical University

Treatments:

Cisplatin
Docetaxel